Safety and Efficacy of Diacerein 1% Ointment for Subjects With Epidermolysis Bullosa Simplex (EBS)
An International, Multicenter, Randomized, Double-Blind, Parallel-Group Phase 2 Study Evaluating the Safety and Efficacy of Diacerein 1% Ointment Topical Formulation in Subjects With Epidermolysis Bullosa Simplex
Sponsor: Castle Creek Pharmaceuticals, LLC
Terminated
Futility
A PHASE2 clinical study on Epidermolysis Bullosa Simplex, this trial is terminated or withdrawn. The trial is conducted by Castle Creek Pharmaceuticals, LLC and has accumulated 18 data snapshots since 2017. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
18 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Terminated PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Terminated PHASE2
▶ Show 13 earlier versions
-
Jan 2021 — Dec 2022 [monthly]
Terminated PHASE2
-
Dec 2019 — Jan 2021 [monthly]
Terminated PHASE2
-
Nov 2018 — Dec 2019 [monthly]
Terminated PHASE2
Status: Recruiting → Terminated
-
Aug 2018 — Nov 2018 [monthly]
Recruiting PHASE2
-
Jul 2018 — Aug 2018 [monthly]
Recruiting PHASE2
-
Jun 2018 — Jul 2018 [monthly]
Recruiting PHASE2
-
May 2018 — Jun 2018 [monthly]
Recruiting PHASE2
-
Mar 2018 — May 2018 [monthly]
Recruiting PHASE2
-
Jan 2018 — Mar 2018 [monthly]
Recruiting PHASE2
-
Oct 2017 — Jan 2018 [monthly]
Recruiting PHASE2
-
Sep 2017 — Oct 2017 [monthly]
Recruiting PHASE2
-
Jul 2017 — Sep 2017 [monthly]
Recruiting PHASE2
-
Jun 2017 — Jul 2017 [monthly]
Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Castle Creek Pharmaceuticals, LLC
For direct contact, visit the study record on ClinicalTrials.gov .